Photocure ASA
OSE:PHO
Net Margin
Photocure ASA
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| NO |
|
Photocure ASA
OSE:PHO
|
1.4B NOK |
-1%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
694B USD |
24%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
365.2B USD |
16%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.9T DKK |
35%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
199.2B CHF |
20%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
177.4B CHF |
23%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
157.8B GBP |
13%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
200.5B USD |
27%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
162.4B USD |
-126%
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
114.1B EUR |
13%
|
Photocure ASA
Glance View
Photocure ASA delivers transformative solutions to improve the lives of bladder cancer patients. The company is headquartered in Oslo, Oslo. The company went IPO on 2000-05-29. The company operates in the field of photodynamic diagnosis, cosmetics and treatment of acne, bladder cancer, colon cancer, as well as human papilloma virus (HPV) and precancerous lesions of the cervix. The Company’s activities comprise research, development and commercialization of pipeline projects within two segments: Cancer and Dermatology. Its brand portfolio includes: Hexvix and Cysview, for detection and management of bladder cancer; Visonac, for acne treatment; Cevira, used in HPV and precancerous lesions of the cervix treatment; and Lumacan, applied in colorectal cancer treatment. Furthermore, It owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. The firm is a parent of a wholly owned entity, Photocure Inc.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Photocure ASA's most recent financial statements, the company has Net Margin of -0.9%.
You don't have any saved screeners yet